UnknownNot Applicable

Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia

China200 participantsStarted 2022-09-01

Plain-language summary

The observational study aimed at evaluating the incidence of systemic mastocytosis associated with t(8;21) AML in patients with de novo t(8;21) AML and their responses to first induction, and the prognosis from standard therapy.

Who can participate

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female, Age (years) \>= 5;
✓. Newly diagnosed as t(8;21) AML patients according to World Health Organization (WHO) classification;
✓. Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.

Exclusion criteria

✕. The t(8;21) AML patients with SM have been diagnosed already;
✕. Patients with drug abuse or long-term alcoholism that affected the evaluation of trial results;
✕. Patients were deemed unsuitable for enrolment by the investigator.

What they're measuring

Incidence of Systemic Mastocytosis associated with t(8;21) Acute Myeloid Leukemia

Timeframe: at 1 year

Trial details

NCT IDNCT05504408

SponsorThe First Affiliated Hospital of Soochow University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-31

Contact for this trial

Suning Chen, professor

+86-13814881746 chensuning@sina.com

View on ClinicalTrials.gov More Systemic Mastocytosis With AHNMD trials